Please assess the completion status of the following clinical trial:

Trial Title: Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Admitted to participating hospital with symptoms suggestive of COVID-19 infection OR develop symptoms of COVID-19 during hospitalization~2. Subject (or legally authorized representative) can provide written informed consent (in English or Spanish) affirming intention to comply with planned study procedures prior to enrollment~3. Male or female adult aged 12 years or older at the time of enrollment~4. Has laboratory-confirmed SARS-CoV-2 infection determined by a validated nucleic acid amplification assay (public health or commercial) in any respiratory specimen collected within 14 days of randomization~5. Illness of any duration that includes~   * Radiographic evidence of pulmonary infiltrates (chest X-ray or CT scan) OR~  * Clinical documentation of lower respiratory symptoms (cough, shortness of breath, wheezing) OR~  * Any documented SpO2 ≤ 94% on room air OR~  * Any inpatient initiation or supplemental oxygen regardless of documented cause~Exclusion Criteria:~1. Participating in any other clinical trial of an experimental agent for COVID-19~2. On hydroxychloroquine at any time during hospitalization, or within 180 days of hospitalization for COVID-19 regardless of indication~3. History of G6PD deficiency, cirrhosis, long QT syndrome or porphyria of any classification~4. Most recent ECG prior to time of screening with QTc of ≥500 msec~5. Known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives~6. Death anticipated within 48 hours of enrollment~7. Inability to obtain informed consent from the patient or designated medical decision maker

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of care (Type: ACTIVE_COMPARATOR): None
- Standard of care plus hydroxychloroquine (Type: EXPERIMENTAL): Standard of care plus hydroxychloroquine for 5 days
- Standard of care plus azithromycin (Type: EXPERIMENTAL): Standard of care plus azithromycin for 5 days
- Standard of care plus hydroxychloroquine plus azithromycin (Type: EXPERIMENTAL): Standard of care plus hydroxychloroquine plus azithromycin for 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).